BOULDER, Colo.--(BUSINESS WIRE)--AstraZeneca PLC dosed its first cancer patient in a Phase 1 clinical trial with our MEK inhibitor, ARRY-704 (AZD8330), triggering a $2 million milestone payment from AstraZeneca to Array BioPharma Inc. (NASDAQ: ARRY). In December 2003, Array partnered the oncology portion of its MEK program, including its lead compound, ARRY-886 (AZD6244), for co-development and commercialization with AstraZeneca. The collaboration included research and development of additional clinical candidates, which resulted in the selection of ARRY-704 in December 2005.
